For a second year in a row, Currax delivered greater than 50% year-over-year revenue growth for CONTRAVE®/MYSIMBA® in 2024. These outsized results were driven by increased patient demand, improved ...
The campaign inspires individuals to seek help in taking control of their weight-loss efforts with CONTRAVE, an established ...
The development and application of an economic model designed to assess the specific costs and benefits of health plan coverage of smoking-cessation programs involving sustained-release bupropion ...